Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Viatris Inc

Get SEC filing alerts via email and in your feed for Viatris Inc

VTRS

Viatris Inc

About Viatris Inc

Viatris is a global healthcare company providing high-quality medicines across multiple therapeutic areas, including generics, branded, complex, and innovative drugs. Serving over 1 billion patients annually in more than 165 countries, it leverages a diversified portfolio, extensive supply chain, and scientific expertise to improve access and address unmet medical needs worldwide. Its business model emphasizes sustainability, strategic partnerships, and expanding innovative product offerings.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Viatris Inc

1
1
Viatris Inc Viatris Reports 8% Revenue Growth to $3.52 Billion in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Viatris Inc Viatris Reports $14.30 Billion Revenue and $3.51 Billion Net Loss for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Viatris Inc Viatris Reports $3.76 Billion in Q3 2025 Revenues, Faces Net Loss of $128.2 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Viatris Inc Viatris Reports 6% Revenue Decline and $4.6 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Viatris Inc Viatris Reports 11% Revenue Decline and $3.04 Billion Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Viatris Inc Viatris Reports Decline in Financial Performance for Q3 and Nine Months of 2024

Via official filing (AI summary) | over 1 year ago | 0 comments